{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-029038","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2025-02-27T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.215046+00:00","generated_at":"2026-05-26T01:56:27.336501+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Athira Pharma FY2024 net loss $96.9M; cash burn continues; ATH-1105 Phase 1 complete; fosgonimeton paused","bullets":["Cash, cash equivalents and investments $51.3M as of Dec 31, 2024, down from $147.4M; net cash used in operations $97.2M.","Net loss $96.9M ($2.52 per share) vs $117.7M ($3.09 per share) in 2023; R&D expenses $70.7M, G&A $26.1M.","Legal expense $4.1M accrued for settlement with DOJ related to NIH grant.","ATH-1105 Phase 1 in 80 healthy volunteers completed with favorable safety; on track to dose ALS patients in 2025.","LIFT-AD Phase 2/3 of fosgonimeton missed endpoints; development paused; exploring strategic alternatives with Cantor Fitzgerald."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-029038","json":"https://secwatch.observer/filing/0000950170-25-029038.json","markdown":"https://secwatch.observer/filing/0000950170-25-029038.md","text":"https://secwatch.observer/filing/0000950170-25-029038.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017025029038/0000950170-25-029038-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017025029038/atha-20250227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T01:56:27.336501+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}